Find Funding Opportunities

Notice Change Key Dates PAR-18-618 NINDS Exploratory Clinical Trials Small Business R44 Clinical Trial Required)" Notice Number: NOT-NS-20-079 Key Dates Release Date: June 29, 2020 Related Announcements PAR-18-618 - NINDS Exploratory Clinical Trials Small Business R44 Clinical Trial Required) Issued National Institute Neurological Disorders Stroke NINDS) Purpose purpose this notice to inform interested applicants a change the Key Dates PAR-18-618 "NINDS Exploratory Clinical Trials Small Business R44 Clinical Trial Required)". Funding Opportunity Announcement been extended one additional council round. dates been modified add following New Application Due Date:April 5, 2021. Changes shown below bold italics. Currently Reads: Part 1. Overview Key Dates: Application Due Date(s) Standard dates apply , 5:00 PM local time applicant organization. *** Note new SBIR/STTR Standard Due Dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Scientific Merit Review Standard dates apply Advisory Council Review Standard dates apply Earliest Start Date Standard dates apply Expiration Date January 6, 2021 Modified Read: Part 1. Overview Key Dates: Application Due Date(s) Standard dates apply , 5:00 PM local time applicant organization. *** Note new SBIR/STTR Standard Due Dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Scientific Merit Review Standard dates apply Advisory Council Review Standard dates apply Earliest Start Date Standard dates apply Expiration Date April 6, 2021 other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: Emily Caporello, Ph.D. National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-1778 Email:Emily.caporello@nih.gov

Notice Extend Eligibility Submission Diversity K22 Applications due COVID–related Disruptions Notice Number: NOT-NS-20-076 Key Dates Release Date: June 26, 2020 Related Announcements PAR-18-469 - NINDS Advanced Postdoctoral Career Transition Award Promote Diversity Neuroscience Research K22-No Independent Clinical Trials) PAR-18-468 - NINDS Advanced Postdoctoral Career Transition Award Promote Diversity Neuroscience Research K22-Clinical Trial Required) Issued National Institute Neurological Disorders Stroke NINDS) Purpose Under normal circumstances, individuals must no than 5 years cumulative postdoctoral research experience i.e. research experience subsequent completion the doctorate) the relevant due date be eligible apply the NINDS K22 Advanced Postdoctoral Career Transition Award Promote Diversity Neuroscience Research. NINDS understands COVID-19 caused major disruption the ability many individuals make progress their research. Though subject future updates, NINDS will provide least 2-receipt cycle extension roughly 8 additional months) eligibility individuals whose eligibility apply the K22, under normal eligibility rules including resubmission policy defined NOT-OD-18-197), expiring between June/July 2020 February/March 2021 inclusive these dates). addition, those normally have eligible apply the June/July 2021 receipt date have 1-receipt cycle roughly 4 months) extension. Example 1: Under normal eligibility rules, final due date which individual apply the K22 June/July 12, 2020. individual now eligible apply the K22 June/July, 2020, October/November 2020 February/March 2021. Example 2: Under normal eligibility rules, final due date which individual apply the K99/R00 February/March 12, 2021. individual now eligible apply the K22 through October/November, 2021 due dates. Example 3: Under normal eligibility rules, final due date which individual apply the K22 June/July 12, 2021. individual now eligible apply the K22 through October/November, 2021 due dates. Example 4: Under normal eligibility rules, final due date which individual apply the K22 February/March 12, 2020. individual no longer eligible the K22. Example 5: individual applied the K22 the February/March, 2020 due date and, under normal eligibility rules, still within eligibility window the June/July, 2020 due date; however, summary statement this individual released after June/July due date. Because review this applicant’s initial submission not completed time the applicant resubmit the June/July 2020 due date, individual does receive extension eligibility is longer eligible apply the K22. Inquiries Please direct inquiries to: Michelle Jones-London, Ph.D. National Institute Neurological Disorders Stroke NINDS)E-mail: NINDSDivesrityTraining@mail.nih.gov

Notice Change Key Dates PAR-18-665 NINDS Renewal Awards SBIR Phase II Grants Phase IIB) Clinical Trials Clinical Research R44 Clinical Trial Optional)" Notice Number: NOT-NS-20-077 Key Dates Release Date: June 26, 2020 Related Announcements PAR-18-665 - NINDS Renewal Awards SBIR Phase II Grants Phase IIB) Clinical Trials Clinical Research R44 Clinical Trial Optional) Issued National Institute Neurological Disorders Stroke NINDS) Purpose purpose this notice to inform interested applicants a change the Key Dates PAR-18-665 "NINDS Renewal Awards SBIR Phase II Grants Phase IIB) Clinical Trials Clinical Research R44 Clinical Trial Optional)". Funding Opportunity Announcement been extended one additional council round. dates been modified add following New Application Due Date:April 5, 2021. Changes shown below bold italics. Currently Reads: Part 1. Overview Key Dates: Application Due Date(s) April 16th thenStandard datesapply , 5:00 PM local time applicant organization. *** Note new SBIR/STTR Standard Due Dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Scientific Merit Review Standard datesapply Advisory Council Review Standard datesapply Earliest Start Date Standard datesapply Expiration Date January 6, 2021 Modified Read: Part 1. Overview Key Dates: Application Due Date(s) April 16th thenStandard datesapply , 5:00 PM local time applicant organization. *** Note new SBIR/STTR Standard Due Dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Scientific Merit Review Standard datesapply Advisory Council Review Standard datesapply Earliest Start Date Standard datesapply Expiration Date April 6, 2021 other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: Emily Caporello, Ph.D. National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-1778 Email:Emily.caporello@nih.gov

Notice Intent Publish Funding Opportunity Announcement BRAIN Initiative Fellows: Ruth L. Kirschstein National Research Service Award NRSA) Individual Postdoctoral Fellowship F32)" Notice Number: NOT-MH-20-062 Key Dates Release Date: June 17, 2020 Estimated Publication Date Funding Opportunity Announcement: August 14, 2020 First Estimated Application Due Date: December 08, 2020 Earliest Estimated Award Date: July 01, 2021 Earliest Estimated Start Date: July 01, 2021 Related Announcements Reissue RFA-MH-18-510 - BRAIN Initiative Fellows: Ruth L. Kirschstein National Research Service Award NRSA) Individual Postdoctoral Fellowship F32) Issued National Institute Mental Health NIMH) National Eye Institute NEI) National Institute Aging NIA) National Institute Alcohol Abuse Alcoholism NIAAA) National Institute Biomedical Imaging Bioengineering NIBIB) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Deafness Other Communication Disorders NIDCD) National Institute Drug Abuse NIDA) National Institute Neurological Disorders Stroke NINDS) National Center Complementary Integrative Health NCCIH) Purpose NIMH, other NIH Institutes Centers participating theBrain Research through Advancing Innovative Neurotechnologies®(BRAIN) Initiative, intends reissue "BRAIN Initiative Fellows: Ruth L. Kirschstein National Research Service Award NRSA) Individual Postdoctoral Fellowship F32)." Notice being provided allow potential applicants sufficient time develop meaningful mentoring teams responsive projects. Funding Opportunity Annoucement FOA) expected be published Summer 2020 an initial expected application due date December 2020. FOA utilize F32 activity code. Details the planned FOA provided below. Research Initiative Details purpose the BRAIN Initiative Fellows F32) program to enhance research training promising postdoctorates, early their postdoctoral training period, have potential become productive investigators research areas will advance goals the BRAIN Initiative. Applications encouraged any research area is aligned one more the seven high-priority areas the BRAIN Initiative, including neuroethics. Applicants expected propose research training an area clearly complements predoctoral research. Formal training analytical tools appropriate the proposed research expected be integral component the research training plan. order maximize training potential the F32 award, program encourages applications individuals have yet completed terminal doctoral degree who expect do within 12 months the application due date. the application due date, candidates not completed than 12 months postdoctoral training. Funding Information Estimated Total Funding TBD Expected Number Awards TBD Estimated Award Ceiling TBD Primary CFDA Numbers 93.242, 93.173, 93.866, 93.853, 93.286, 93.213, 93.867, 93.865, 93.279, 93.273 Anticipated Eligible Organizations Public/State Controlled Institution Higher EducationPrivate Institution Higher EducationNonprofit 501(c)(3) IRS Status than Institution Higher Education)Small BusinessFor-Profit Organization than Small Business)Eligible Agencies the Federal GovernmentNon-domestic non-U.S.) Entity Foreign Organization) Applications not being solicited this time. Inquiries Please direct inquiries to: Ashlee Van’t Veer, PhD National Institute Mental Health NIMH) 301-443-3107 BRAIN.Initiative.Training@nih.gov

Notice Extension the Response Date NOT-NS-20-026 Request Information: Soliciting Input Areas Health Disparities Inequities Neurological Disease and/or Care the United States Across Lifespan" Notice Number: NOT-NS-20-075 Key Dates Release Date: June 8, 2020 Related Announcements NOT-NS-20-026 - Request Information: Soliciting Input Areas Health Disparities Inequities Neurological Disease and/or Care the United States Across Lifespan Issued National Institute Neurological Disorders Stroke NINDS) Purpose Purpose Notice extends response date NOT-NS-20-026 " Request Information: Soliciting Input Areas Health Disparities Inequities Neurological Disease and/or Care the United States Across Lifespan." following section NOT-NS-20-026 been updated: Key Dates Current Response Date: June 15, 2020 New Response Date:July 15, 2020 other aspects the RFI remain same. Inquiries Please direct inquiries to: NINDS Office Global Health Health Disparities Email:OGHHDRFI@NINDS.NIH.GOV

Notice Interest Advancing Research FMR1-Associated Conditions Notice Number: NOT-HD-20-009 Key Dates Release Date: June 5, 2020 Related Announcements RFA-HD-20-003 - Centers Collaborative Research Fragile X andFMR1-Associated Conditions P50 Clinical Trial Optional) NOT-HD-17-033 - Request Information RFI): Future Directions Research Fragile X Syndrome FMR1-Related Conditions Issued Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Mental Health NIMH) National Institute Neurological Disorders Stroke NINDS) National Center Advancing Translational Sciences NCATS) Purpose FMR1-associated conditions a collection disparate conditions all stem cytosine-guanine-guanine CGG) nucleotide repeat expansions the 5’ untranslated region the FMR1 gene, located the human X chromosome. conditions include: Fragile X Syndrome FXS), most common inherited cause intellectual developmental disability IDD) Fragile X-associated Tremor/Ataxia Syndrome FXTAS), leads disabling neurological symptoms middle-age elderly adults Fragile X-associated Primary Ovarian Insufficiency FXPOI), can lead infertility and/or early menopause women FMR1 mutations categorized the number CGG repeats. Full mutation: than 200 repeats. Individuals FXS carry full mutation. Premutation: 55-200 repeats. Individuals FXTAS FXPOI carry premutation. Gray zone: 44-55 repeats Typical: 23-45 repeats Low Zone: fewer 23 repeats addition the three specific FMR1-associated conditions listed above, recent research advances suggest FMR1 mutations various sizes also linked a range additional symptoms conditions. NIH support research FMR1-associated conditions ranges basic genetic, molecular, vitro cellular, cell animal models human clinical research. NIH efforts also span multiple institutes offices, reflecting wide-ranging importance NIH generating knowledge improve health individuals FMR1-associated conditions. recognition the rapidly evolving landscape FMR1-associated research, NIH recently published Strategic Plan Research FMR1-Associated Conditions. Strategic Plan, was developed collaboration the Fragile X community, articulates NIH’s current research priorities, are directed toward overarching vision accelerating development effective interventions prevent treat FMR1-associated conditions. purpose this Notice to encourage new applications support basic, translational and/or clinical research the causes, diagnosis, prevention treatment FMR1-associated conditions the Eunice Kennedy Shriver National Institute Child Health Human Development NICHD), National Institute Mental Health NIMH), National Institute Neurological Disorders Stroke NINDS) the National Center Advancing Translational Sciences NCATS). Applications should submitted through existing Funding Opportunity Announcements FOAs) supported NICHD, NIMH, NINDS NCATS. applications should respond both one more goal areas identified the FMR1 Strategic Plan to priorities the Institute(s) Center(s) which application being submitted. variety Parent institute-specific FOAs available applicants, including Research R), Cooperative Agreement U), Career Development K), Fellowship F) awards which NICHD, NIMH, NINDS NCATS participate. Individual institutes have specific requirements certain mechanisms study types, particularly clinical trials; institutes also different interests funding priorities FMR1 research. Therefore, applicants strongly encouraged discuss any specific applications the program contacts listed below guidance selecting appropriate NIH institute/center FOA. Inquiries Please direct inquiries to: Tracy King, M.D., M.P.H. Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) Telephone: 301-402-1822 Email: tracy.king@nih.gov Bettina Buhring, Ph.D. National Institute Mental Health NIMH) Phone: 301-443-1576 Email: bettina.buhring@nih.gov Lisa Gilotty, Ph.D. National Institute Mental Health NIMH) Phone: 301-443-3825 Email: gilottyl@mail.nih.gov Laura Mamounas, Ph.D. National Institute Neurological Disorders Stroke NINDS) Phone: 301-496-5745 Email: mamounal@ninds.nih.gov Robert Riddle, Ph.D. National Institute Neurological Disorders Stroke NINDS) Phone: 301-496-5745 Email: riddler@ninds.nih.gov Tiina Urv, Ph.D. National Center Advancing Translational Sciences NCATS) Telephone: 301-827-2746 Email: urvtiin@mail.nih.gov

Notice Change Eligible Activity Codes NOT-NS-20-051 Notice Special Interest: Availability Urgent Competitive Revisions Administrative Supplements Research Biological Effects the 2019 Novel Coronavirus the Nervous System" Notice Number: NOT-NS-20-074 Key Dates Release Date: 27, 2020 Related Announcements NOT-NS-20-051 - Notice Special Interest NOSI): Availability Urgent Competitive Revisions Administrative Supplements Research Biological Effects the 2019 Novel Coronavirus the Nervous System PA-18-591 - Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional) PA-18-935 - Urgent Competitive Revision Existing NIH Grants Cooperative Agreements Urgent Supplement Clinical Trial Optional) Issued National Institute Neurological Disorders Stroke NINDS) Purpose purpose this notice to inform interested applicants a change the eligible activity codes NOT-NS-20-051 "Notice Special Interest NOSI): Availability Urgent Competitive Revisions Administrative Supplements Research Biological Effects the 2019 Novel Coronavirus the Nervous System". Effective immediately,the RF1 activity codewill added an eligible activity codeto NOT-NS-20-051, applications submitted both, PA-18-591 "Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional) " PA-18-935 "Urgent Competitive Revision Existing NIH Grants Cooperative Agreements Urgent Supplement - Clinical Trial Optional)". changes below bold italics. Currently Reads: Purpose Application Submission Information Applications this initiative must submitted using of following opportunity announcements the subsequent reissued equivalent. PA-18-591 - Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional) PA-18-935 - Urgent Competitive Revision Existing NIH Grants Cooperative Agreements Urgent Supplement - Clinical Trial Optional) Applications research fall within scope an existing NINDS award should submitted through PA-18-591 Parent Admin Supp Clinical Trial Optional). Eligible activity codes limited the mechanisms listed PA-18-591. Applications research involve change the original scope an active award, still falls within mission the NINDS must apply through PA-18-935 Urgent Competitive Revision Existing NIH Grants Cooperative Agreements Urgent Supplement - Clinical Trial Optional). Eligible activity codes applications PA-18-935 limited the following mechanisms: P01, P50, R00, R01, R03, R15, R21, R33, R35, R41, R42, R43, R44, R61, U01, U19, U24, U44, U54, UG3, UH3). Modified Read: Purpose Application Submission Information Applications this initiative must submitted using of following opportunity announcements the subsequent reissued equivalent. PA-18-591 - Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional) PA-18-935 - Urgent Competitive Revision Existing NIH Grants Cooperative Agreements Urgent Supplement - Clinical Trial Optional) Applications research fall within scope an existing NINDS award should submitted through PA-18-591 Parent Admin Supp Clinical Trial Optional). Eligible activity codes limited the mechanisms listed PA-18-591, addition the RF1 mechanism. Applications research involve change the original scope an active award, still falls within mission the NINDS must apply through PA-18-935 Urgent Competitive Revision Existing NIH Grants Cooperative Agreements Urgent Supplement - Clinical Trial Optional). Eligible activity codes applications PA-18-935 limited the following mechanisms: P01, P50, RF1, R00, R01, R03, R15, R21, R33, R35, R41, R42, R43, R44, R61, U01, U19, U24, U44, U54, UG3, UH3) other aspects this Notice Special Interest remain unchanged. Inquiries Please direct inquiries to: Please contact program officer your active award.

Request Information RFI) Developing Online Educational Resource Training the Principles Rigorous Research Notice Number: NOT-NS-20-062 Key Dates Release Date: 13, 2020 Response Date: August 01, 2020 Related Announcements None Issued National Institute Neurological Disorders Stroke NINDS) Purpose purpose this Request Information RFI) to solicit public input the best approaches providing accessible education the principles rigorous biomedical research members the scientific community. Rigorous research practices transparent reporting methods results vital the process scientific validation. way improve practice to improve training the principles rigorous research all career stages. an online educational resource be successful, should accessible, effective, adaptable, are attributes can implemented using variety approaches. especially encourage experts training, rigorous experimental design implementation, mentoring, education, technology contribute this RFI. Background Rigorous experimental design conduct, conjunction transparent reporting, vital appropriate validity interpretation scientific results. Training the fundamental principles rigorous research how implement rigorous experimental design reporting essential the scientific enterprise. Such principles include, are limited to, consideration experimenter biases, confounding factors, clearly defined assumptions, descriptions uncertainty, proper interpretation, full disclosure how data collected analyzed. this reason, National Institute Neurological Disorders Stroke NINDS) held workshop how best instill fundamental principles rigorous research. resulting publication this workshop suggests improved training all career stages better engagement all members the scientific community needed change culture science around issues rigor transparency. discussed this paper, any educational resource addressing issue need be freely available, easily discoverable, engaging, modular, adaptable, upgradeable. will also need use most effective teaching principles techniques, including expressing relevance, building self-efficacy, assessing behavioral change the end-user. NINDS created website facilitate efforts identify current online educational resources these topics. Participation various sectors the scientific enterprise be necessary improve training change culture, this website also describes effort bring scientists together collaborate such issues. NINDS seeking broader input the content format best conveying principles rigorous research the scientific community well effective ways encourage uptake dissemination these principles. encourage collaboration between scientists educational experts responding this RFI. Information Requested NINDS requests public input best practices innovative ideas education the principles rigorous research well promotion rigorous research practices. Responses especially encouraged the following questions: are most important principles rigorous research all scientists understand? each career stage undergraduates, graduates, post-docs, faculty), are best teaching practices use i.e. to convey information a lasting impactful way)? each career stage, is ideal delivery structure how often should principles reinforced? delivered an online resource, is most effective balance between different educational media e.g. text, video, interactive activities)? to Submit Response may respond this RFI filling this webform submitting email RigorChampions@nih.gov August 1, 2020. submitting email, please include Notice number NOT-NS-20-062) the subject line. Responding this RFI voluntary. Responses address any all aspects the information requested other relevant topics pertinent consideration NINDS. NINDS staff use discretion considering responses submitted after comment period closed. Respondents not receive individualized feedback concerning responses. Proprietary, classified, confidential, sensitive information should be included your response. Government reserves right use non-proprietary technical information any resultant solicitation(s), summaries, other materials. RFI for information planning purposes only should be construed a policy, solicitation applications, an obligation the part the Federal Government, National Institutes Health, NINDS provide support any ideas identified response it. Please note NINDS does intend make any awards based responses this RFI to otherwise pay the preparation any information submitted for Government's of such information. Inquiries Please direct inquiries to: Devon Crawford, Ph.D. National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-1917 Email: devon.crawford@nih.gov

Notice Change Research Strategy RFA-NS-20-016 Biological Measures Prognosing Monitoring Persistent Concussive Symptoms Early Middle Adolescents: Center Without Walls PCS-EMA CWOW) U54 Clinical Trial Allowed)" Notice Number: NOT-NS-20-052 Key Dates Release Date: 12, 2020 Related Announcements RFA-NS-20-016 Issued National Institute Neurological Disorders Stroke NINDS) Purpose purpose this notice to inform potential applicants a change the Research Objectives Research Strategy RFA-NS-20-016 "Biological Measures Prognosing Monitoring Persistent Concussive Symptoms Early Middle Adolescents: Center Without Walls PCS-EMA CWOW) U54 Clinical Trial Allowed)." change be effective the June 26, 2020 receipt date. Changes shown bold italics below. Currently Reads: Part 2. Full Text Announcement Section I. Funding Opportunity Description Specific Research Objectives FOA solicits multicenter applications multidisciplinary groups order develop, then perform initial clinical validation objective biological measures improve accuracy prognosticating / monitoring persistent concussive symptoms result concussion and/or repetitive head impacts adolescent populations. overarching goal this program to develop validate biological measures will improve prognosis persistent concussive symptoms EMA patients accounts and sensitive individual variability symptom presentation. scientific project must include three parts: 1) development phase, 2) initial clinical validation phase, 3) description how validated biological measures be incorporated a risk stratification algorithm persistent concussive symptoms. Development phase: the development stage, research project should focus determining sensitivity specificity one more biological measures prognosing and/or monitoring persistent concussive symptoms an EMA population. Where feasible, biological measure should collected across research sites. Initial clinical validation phase: new independent cohort must recruited tested the full set biological measurements be validated using parameters context use obtained the development phase. Part 2. Full Text Announcement Section IV. Application Submission Information Overall Component PHS 398 Research Plan Overall) Research Strategy: Overall Research Strategy should describe PCS-EMA CWOW's goals objectives, background information, the overall importance including biological measures the prognosis monitoring persistent concussive symptoms an adolescent population. Describe rationale the proposed program how site uniquely positioned contribute world-class expertise cutting-edge resources towards addressing aims. Describe rationale choosing biological measure combination biological measures including feasibility use clinical settings future clinical trials. Describe need any proposed research cores how will interact the projects the Administrative core. Explain strategy achieving goals defined the overall Center, the research project research cores relate that strategy, a transition plan moving the development phase the initial clinical validation the biological measures a risk stratification algorithm. Clearly describe context(s) under the biological measure(s) be used. context(s) description should include is limited to: point care, clinical presentation the population e.g. patient groups specific concussive symptom clusters), mechanism injury. biological measures risk stratification algorithm should practical, efficient, implementable the appropriate clinical settings where patients present; e.g., emergency departments, urgent care clinics, sports medicine clinics, primary care offices. Describe plan developing a resource the broader research community including policies access collaborations. Describe the data sharing resource developed this Center serve accelerate research knowledge persistent concussive symptoms adolescents. Modified Read: Part 2. Full Text Announcement Section I. Funding Opportunity Description Specific Research Objectives FOA solicits multicenter applications multidisciplinary groups order develop, then perform initial clinical validation three more objective biological measures improve accuracy prognosticating / monitoring persistent concussive symptoms result concussion and/or repetitive head impacts adolescent populations. overarching goal this program to develop validate biological measures will improve prognosis persistent concussive symptoms EMA patients accounts and sensitive individual variability symptom presentation. scientific project must include three parts: 1) development phase, 2) initial clinical validation phase, 3) description how validated biological measures be incorporated a risk stratification algorithm persistent concussive symptoms. Development phase: the development stage, research project should focus determining sensitivity specificity each the biological measures specific combinations the biological measures prognosing and/or monitoring persistent concussive symptoms an EMA population. Where feasible, biological measure should collected across research sites. Initial clinical validation phase: new independent cohort must recruited tested the full set biological measurements be validated using parameters context use obtained the development phase. Part 2. Full Text Announcement Section IV. Application Submission Information Overall Component PHS 398 Research Plan Overall) Research Strategy: Overall Research Strategy should describe PCS-EMA CWOW's goals objectives, background information, the overall importance including biological measures the prognosis monitoring persistent concussive symptoms an adolescent population. Describe rationale the proposed program how site uniquely positioned contribute world-class expertise cutting-edge resources towards addressing aims. Describe rationale choosing of biological measures combination biological measures including feasibility use clinical settings future clinical trials. Describe need any proposed research cores how will interact the projects the Administrative core. Explain strategy achieving goals defined the overall Center, the research project research cores relate that strategy, a transition plan moving the development phase the initial clinical validation the biological measures a risk stratification algorithm. Clearly describe context(s) under the biological measure(s) be used. context(s) description should include is limited to: point care, clinical presentation the population e.g. patient groups specific concussive symptom clusters), mechanism injury. biological measures risk stratification algorithm should practical, efficient, implementable the appropriate clinical settings where patients present; e.g., emergency departments, urgent care clinics, sports medicine clinics, primary care offices. Describe plan developing a resource the broader research community including policies access collaborations. Describe the data sharing resource developed this Center serve accelerate research knowledge persistent concussive symptoms adolescents. aspects this FOA remain unchanged. Inquiries Please direct inquiries to: Patrick SF Bellgowan, Ph.D. Repair Plasticity Cluster, National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-1447 Email: psfb@mail.nih.gov

Notice Extend RFA-MH-20-120 BRAIN Initiative: Secondary Analysis Archiving BRAIN Initiative Data R01 Clinical Trial Allowed) Notice Number: NOT-MH-20-052 Key Dates Release Date: 11, 2020 Related Announcements RFA-MH-20-120 Issued National Institute Mental Health NIMH) National Eye Institute NEI) National Institute Aging NIA) National Institute Alcohol Abuse Alcoholism NIAAA) National Institute Biomedical Imaging Bioengineering NIBIB) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Deafness Other Communication Disorders NIDCD) National Institute Drug Abuse NIDA) National Institute Neurological Disorders Stroke NINDS) National Center Complementary Integrative Health NCCIH) Purpose purpose this Notice to extend RFA-MH-20-120, BRAIN Initiative: Non-Invasive Neuromodulation - New Tools Techniques Spatiotemporal Precision R01 Clinical Trial Optional) Part 1. Overview Information Key Dates Currently reads: Application Due Date(s) September 6, 2019 June 11, 2020, 5:00 PM local time applicant organization. types non-AIDS applications allowed this funding opportunity announcement due these dates. late applications be accepted this Funding Opportunity Announcement. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. AIDS Application Due Date(s) Applicable Scientific Merit Review: March 2020 October 2020 Advisory Council: 2020, January 2021 Earliest Start Date: July 2020, April 2021 Expiration Date: June 12, 2020 Modified read: Application Due Date(s) September 6, 2019, June 11, 2020, February 26, 2021 5:00 PM local time applicant organization. types non-AIDS applications allowed this funding opportunity announcement due these dates. late applications be accepted this Funding Opportunity Announcement. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. AIDS Application Due Date(s) Applicable Scientific Merit Review March 2020 October 2020, June 2021 Advisory Council 2020, January 2021, August 2021 Earliest Start Date July 2020, April 2021, September 2021 Expiration Date February 27, 2021 other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: Ming Zhan, Ph.D. National Institute Mental Health NIMH) Telephone: 301-827-3678 Email: ming.zhan@nih.gov